B-cell Acute Lymphoblastic Leukemia

• CLINICAL_TRIALS research · 2019-01-31
  Clinical Trial Update: A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL [EARLY_Phase 1]

  An early-phase study of GC022 CAR-T cell immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia, sponsored by Hebei Ya…

• CLINICAL_TRIALS research · 2017-10-20
  Clinical Trial Update: CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. [Phase 1, Phase 2]

  A Phase 1/2 clinical trial evaluating CD19 CAR-T cells for relapse or refractory CD19-positive B-cell acute lymphoblastic leukemia. The curr…

• CLINICAL_TRIALS research · 2017-05-17
  Clinical Trial Update: Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia

  The update summarizes biomarker analyses performed on samples from patients with B-cell acute lymphoblastic leukemia. The study status is co…

• CLINICAL_TRIALS research · 2016-06-09
  Clinical Trial Update: CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies [Phase 1, Phase 2]

  This entry reports a phase 1/2 clinical trial of a CD22-targeted CAR-T therapy for recurrent or refractory B-cell malignancies; the status i…

• CLINICAL_TRIALS research · 2016-02-03
  Clinical Trial Update: A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia [Phase 1, Phase 2]

  A clinical trial update describing a Phase 1/2 study evaluating CD19-targeted immunotherapy T cells in patients with relapsed or refractory …

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2014-07-14
  Clinical Trial Update: Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL) [Phase 1, Phase 2]

  This entry outlines a Phase 1/2 clinical trial (MARALL) evaluating monoclonal antibodies for recurrent or refractory B-cell acute lymphoblas…